{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:12:44Z","timestamp":1780499564430,"version":"3.54.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.jaci.2007.11.030","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T11:31:41Z","timestamp":1200483101000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["B cell\u2013directed therapies for autoimmune disease and correlates of disease response and relapse"],"prefix":"10.1016","volume":"121","author":[{"given":"Marc C.","family":"Levesque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. William","family":"St. Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2007.11.030_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.21525","article-title":"New prospects for autoimmune disease therapy: B cells on deathwatch","volume":"54","author":"St Clair","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib2","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.22020","article-title":"Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms","volume":"54","author":"Silverman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaci.2007.11.030_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The therapeutic potential of anti-CD20 \u201cwhat do B-cells do?\u201d","volume":"117","author":"Eisenberg","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib5","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/art.21937","article-title":"B\u00a0cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder","volume":"54","author":"Goldenberg","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2007.11.030_bib7","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jaci.2007.11.030_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.hoc.2004.04.008","article-title":"Antibody therapy for chronic lymphocytic leukemia: a promising new modality","volume":"18","author":"Lin","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaci.2007.11.030_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2006.03.010","article-title":"B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?","volume":"121","author":"Stohl","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib12","first-page":"430","article-title":"Serum sickness following treatment with rituximab","volume":"34","author":"Todd","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaci.2007.11.030_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2007.11.030_bib15","first-page":"3","article-title":"Rituxan warning","volume":"41","year":"2007","journal-title":"FDA Consumer"},{"key":"10.1016\/j.jaci.2007.11.030_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib17","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib19","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib20","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib21","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2007.11.030_bib22","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/art.21351","article-title":"B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus","volume":"52","author":"Marks","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib23","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2141.2006.06024.x","article-title":"The pathogenesis of immune thrombocytopaenic purpura","volume":"133","author":"Cooper","year":"2006","journal-title":"Br\u00a0J Haematol"},{"key":"10.1016\/j.jaci.2007.11.030_bib25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2230.2006.02331.x","article-title":"Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy","volume":"32","author":"Hoque","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2007.11.030_bib28","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2165\/00003495-200666150-00004","article-title":"B-cell-targeted therapy for systemic lupus erythematosus","volume":"66","author":"Sabahi","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2007.11.030_bib29","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2005.045898","article-title":"Rituximab in the treatment of antisynthetase syndrome","volume":"65","author":"Brulhart","year":"2006","journal-title":"Annals Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib33","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2007.11.030_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2007.11.030_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jaci.2007.11.030_bib36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2007.11.030_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2007.11.030_bib38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2007.11.030_bib39","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaci.2007.11.030_bib40","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02813430510015269","article-title":"Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response","volume":"34","author":"Omdal","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaci.2007.11.030_bib43","unstructured":"Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, Fox R, et\u00a0al. A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS). 2007. http:\/\/www.abstracts2view.com\/aan2007boston\/view.php?nu=AAN07L_S12.003. Accessed November 30, 2007."},{"key":"10.1016\/j.jaci.2007.11.030_bib44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0952-7915(95)80037-9","article-title":"B cell activation, tolerance and antigen-presenting function","volume":"7","author":"Hodgkin","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1146\/annurev.iy.08.040190.004013","article-title":"Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes","volume":"8","author":"Lanzavecchia","year":"1990","journal-title":"Ann Rev Immunol"},{"issue":"suppl 4","key":"10.1016\/j.jaci.2007.11.030_bib47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1010","article-title":"Roles of B cells in rheumatoid arthritis","volume":"5","author":"Silverman","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2007.11.030_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000082086","article-title":"Regulatory roles for cytokine-producing B cells in infection and autoimmune disease","volume":"8","author":"Lund","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.jaci.2007.11.030_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/82717","article-title":"Reciprocal regulation of polarized cytokine production by effector B and T cells","volume":"1","author":"Harris","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib50","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.4049\/jimmunol.161.8.3836","article-title":"Transfer of primitive stem\/progenitor bone marrow cells from LT alpha-\/- donors to wild-type hosts: implications for the generation of architectural events in lymphoid B cell domains","volume":"161","author":"Mebius","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib51","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S0140-6736(04)16154-0","article-title":"Autoantibodies as predictors of disease","volume":"363","author":"Scofield","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2007.11.030_bib52","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood.V106.11.4006.4006","article-title":"Rituximab therapy induces long lasting clinical remissions and reduction of anti-platelet glycoprotein autoantibodies in patients with chronic immune thrombocytopenic purpura (ITP)","volume":"106","author":"Ahn","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.11.030_bib53","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantapaa-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/art.10117","article-title":"How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis","volume":"46","author":"Visser","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/ard.51.9.1029","article-title":"Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study","volume":"51","author":"van Zeben","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib57","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/art.1780330505","article-title":"Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study","volume":"33","author":"ter Borg","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1172\/JCI1316","article-title":"Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies","volume":"101","author":"Schellekens","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2007.11.030_bib59","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib60","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.179.4.1083","article-title":"Autoimmunity and apoptosis","volume":"179","author":"Tan","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib61","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","article-title":"Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE","volume":"122","author":"Vallerskog","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib64","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archneur.62.10.1620","article-title":"Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis","volume":"62","author":"Stuve","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jaci.2007.11.030_bib65","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jaci.2007.11.030_bib66","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","article-title":"A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus","volume":"189","author":"Chan","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V96.1.9","article-title":"Fates of human B-cell precursors","volume":"96","author":"LeBien","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.11.030_bib68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1084\/jem.20050218","article-title":"Selecting B cells and plasma cells to memory","volume":"201","author":"Dorner","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib69","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0167-5699(98)01330-9","article-title":"B-cell development: a comparison between mouse and man","volume":"19","author":"Ghia","year":"1998","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaci.2007.11.030_bib70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4065\/81.3.377","article-title":"B cells in health and disease","volume":"81","author":"Carter","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaci.2007.11.030_bib71","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1182\/blood-2004-11-4284","article-title":"Identification and characterization of circulating human transitional B cells","volume":"105","author":"Sims","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.11.030_bib72","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood.V98.8.2498","article-title":"Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry","volume":"98","author":"McKenna","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.11.030_bib73","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1074-7613(00)80357-X","article-title":"Changes in the V(H) gene repertoire of developing precursor B lymphocytes in mouse bone marrow mediated by the pre-B cell receptor","volume":"7","author":"ten Boekel","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2007.11.030_bib74","doi-asserted-by":"crossref","first-page":"18470","DOI":"10.1074\/jbc.274.26.18470","article-title":"Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells","volume":"274","author":"Muramatsu","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2007.11.030_bib75","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nature714","article-title":"Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas","volume":"415","author":"Martin","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2007.11.030_bib76","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","article-title":"Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells","volume":"188","author":"Klein","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib77","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.167.7.3610","article-title":"Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome","volume":"167","author":"Bohnhorst","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib78","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood.V99.6.2154","article-title":"The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression","volume":"99","author":"Medina","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.11.030_bib79","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1182\/blood-2006-08-043414","article-title":"T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue","volume":"109","author":"Withers","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2007.11.030_bib80","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2007.11.030_bib81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","article-title":"Pharmacokinetics of rituximab and its clinical use: thought for the best use?","volume":"62","author":"Cartron","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaci.2007.11.030_bib82","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2007.11.030_bib83","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib84","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib85","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.174.7.4389","article-title":"The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice","volume":"174","author":"Hamaguchi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib86","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib87","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib88","doi-asserted-by":"crossref","first-page":"R714","DOI":"10.1186\/ar1731","article-title":"Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody","volume":"7","author":"Rouziere","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2007.11.030_bib89","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib91","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/ard.2004.030684","article-title":"Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma","volume":"64","author":"Pijpe","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib92","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/art.22603","article-title":"BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome","volume":"56","author":"Pers","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib93","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib94","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib95","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1600-6143.2004.00502.x","article-title":"Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses","volume":"4","author":"Agarwal","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2007.11.030_bib96","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-2141.2006.06482.x","article-title":"Epstein-Barr virus T-cell immunity despite rituximab","volume":"136","author":"Nehring","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2007.11.030_bib97","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","article-title":"Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis","volume":"123","author":"Sfikakis","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib99","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2007.11.030_bib100","first-page":"S149","article-title":"Immunoglobulin levels and infection rates in patients with rheumatoid arthritis (RA) treated with repeated courses of rituximab","volume":"56","author":"Genovese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-6143.2003.00646.x","article-title":"Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174","volume":"5","author":"Bearden","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2007.11.030_bib102","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/clim.2000.4980","article-title":"Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab)","volume":"98","author":"Gonzalez-Stawinski","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib103","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib104","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0889-857X(05)70205-2","article-title":"Pathogenesis of rheumatoid arthritis: role of B lymphocytes","volume":"27","author":"Zhang","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"issue":"suppl 2","key":"10.1016\/j.jaci.2007.11.030_bib105","article-title":"B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?","volume":"44","author":"Panayi","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2007.11.030_bib106","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib107","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/art.22629","article-title":"Six refractory lupus patients treated with rituximab: a case series","volume":"57","author":"Gillis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib108","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2006.067124","article-title":"B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response","volume":"66","author":"Ng","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib109","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.0105-2896.2005.00219.x","article-title":"The role of BAFF in immune function and implications for autoimmunity","volume":"204","author":"Kalled","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2007.11.030_bib111","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib112","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib113","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2007.11.030_bib114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and\u00a0efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib115","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2007.11.030_bib116","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.192.7.953","article-title":"Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response","volume":"192","author":"Do","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2007.11.030_bib117","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.4049\/jimmunol.175.9.6143","article-title":"Innate immunity and human B cell clonal expansion: effects on the recirculating B2 subpopulation","volume":"175","author":"Mongini","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib118","first-page":"S780","article-title":"Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab","volume":"54","author":"Stohl","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib119","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/toxsci\/kfj148","article-title":"Chronic\u00a0administration of belimumab, a BLyS antagonist, decreases tissue and\u00a0peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects","volume":"91","author":"Halpern","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jaci.2007.11.030_bib120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2007.11.030_bib121","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2007.11.030_bib122","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2007.06584.x","article-title":"Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation","volume":"137","author":"Nishio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2007.11.030_bib123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/rheumatology\/kel148","article-title":"Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy","volume":"46","author":"Leandro","year":"2007","journal-title":"Rheumatology"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674907022695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674907022695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:10:58Z","timestamp":1758777058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674907022695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0091674907022695"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2007.11.030","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell\u2013directed therapies for autoimmune disease and correlates of disease response and relapse","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2007.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}